In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition.
- Identification of Prognostic Genomic Alterations: This research delves into the genomic landscape of dogs with osteosarcoma to identify key genetic mutations. The study reveals that KDR and KMT2D mutations serve as prognostic markers for poor survival, shedding light on the underlying genetics of this aggressive tumor.
- Improved Survival with Targeted Therapy: The study demonstrates a significant increase in median survival time for dogs with TP53 mutations when treated with vorinostat, an HDAC inhibitor. The findings underscore the potential of targeted therapy in enhancing survival outcomes, offering new hope for osteosarcoma patients with TP53 mutations.
- Accelerating Translational Cancer Research: By confirming these associations with the FidoCure® database, this research paves the way for accelerated clinical studies and the development of novel treatments, not only benefiting dogs with osteosarcoma but also holding promise for advancements in human cancer research.
We believe that these findings are not only pertinent to our community of veterinarians and researchers but also hold the potential to impact the lives of our beloved patients who face this daunting diagnosis.